MX2015008329A - Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. - Google Patents
Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.Info
- Publication number
- MX2015008329A MX2015008329A MX2015008329A MX2015008329A MX2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion partners
- listerial
- expression
- preparation
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona ácidos nucleicos, sistemas de expresión, y cepas de vacuna que proporcionan una expresión y secreción eficientes de antígenos de interés en el citosol de las células huésped, y respuestas efectivas de las células T CD4 y CD8 mediante la vinculación funcional de Listerial y otros péptidos señal bacterial/acompañantes de secreción como compañeros de fusión de terminal N en el marco de lectura transaccional con los antígenos de proteína codificados recombinantes. Estos compañeros de fusión terminal N se eliminan (ya sea por eliminación real, por mutación o por combinación de estos enfoques) para cualquiera de las secuencias nativas PEST a la secuencia, y/o para ciertos residuos hidrofóbicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261746237P | 2012-12-27 | 2012-12-27 | |
US201361780744P | 2013-03-13 | 2013-03-13 | |
PCT/US2013/078119 WO2014106123A1 (en) | 2012-12-27 | 2013-12-27 | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015008329A true MX2015008329A (es) | 2016-03-01 |
Family
ID=51017446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008329A MX2015008329A (es) | 2012-12-27 | 2013-12-27 | Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US9663557B2 (es) |
EP (1) | EP2938627B1 (es) |
JP (2) | JP2016503655A (es) |
KR (1) | KR102160322B1 (es) |
CN (1) | CN104955835B (es) |
AU (2) | AU2013370210B2 (es) |
BR (1) | BR112015015076A2 (es) |
CA (1) | CA2888727A1 (es) |
EA (1) | EA201590397A8 (es) |
HK (1) | HK1215260A1 (es) |
MX (1) | MX2015008329A (es) |
SG (2) | SG11201502792TA (es) |
WO (1) | WO2014106123A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
US20110129499A1 (en) | 2008-05-19 | 2011-06-02 | Paulo Maciag | Dual delivery system for heterologous antigens |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
JP5981436B2 (ja) | 2010-10-01 | 2016-08-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用 |
EP2683400A4 (en) | 2011-03-11 | 2014-09-17 | Advaxis | ADJUVANZIA ON LISTERIA BASE |
US10058599B2 (en) | 2012-03-12 | 2018-08-28 | Advaxis, Inc. | Suppressor cell function inhibition following Listeria vaccine treatment |
SG11201701149SA (en) | 2014-07-18 | 2017-04-27 | Advaxis Inc | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
US10925945B2 (en) | 2014-10-13 | 2021-02-23 | Providence Health & Services-Oregon | Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof |
PT3253865T (pt) * | 2015-02-06 | 2022-10-03 | Nat Univ Singapore | Métodos para melhorar a eficácia das células imunitárias terapêuticas |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
US10105427B2 (en) * | 2015-04-13 | 2018-10-23 | Aduro Biotech, Inc. | Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same |
JP2018512165A (ja) * | 2015-04-13 | 2018-05-17 | アデュロ バイオテック,インコーポレイテッド | 癌の治療のための免疫原性融合タンパク質 |
AU2016262823A1 (en) * | 2015-05-18 | 2017-12-07 | Universita' Degli Studi Di Trento | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
IL305238A (en) | 2015-12-16 | 2023-10-01 | Gritstone Bio Inc | Identification of neoantigens, preparation, and use |
EP3692996A1 (en) * | 2016-03-18 | 2020-08-12 | Immune Sensor, LLC | Cyclic di-nucleotide compounds and methods of use |
US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
WO2019032916A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTES WITH LYMPHOCYTE T-RECEPTOR DEFICIENTS AND METHODS OF USE THEREOF |
IL273255B1 (en) | 2017-09-19 | 2024-06-01 | Advaxis Inc | Preparations and methods for lyophilization of bacterial strains and listeria |
KR20200087143A (ko) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | 핫스팟을 이용한 신생항원 동정 |
CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
KR20200130399A (ko) | 2018-03-09 | 2020-11-18 | 어드박시스, 인크. | 리스테리아 균주의 약독화 및 감염성을 평가하기 위한 조성물 및 방법 |
EP3536706A1 (en) | 2018-03-09 | 2019-09-11 | BiOMVis Srl | Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof |
CN110408634B (zh) | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
WO2019210034A1 (en) | 2018-04-27 | 2019-10-31 | Advaxis, Inc. | Compositions and methods for evaluating potency of listeria-based immunotherapeutics |
EP3725371A1 (en) | 2019-04-18 | 2020-10-21 | BiOMVis Srl | Method for the production of outer membrane vesicles and immunogenic compositions thereof |
CN110499324A (zh) * | 2019-09-02 | 2019-11-26 | 中生康元生物科技(北京)有限公司 | 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
US5783415A (en) | 1991-03-29 | 1998-07-21 | Genentech, Inc. | Method of producing an IL-8 receptor polypeptide |
IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
US6379943B1 (en) | 1999-03-05 | 2002-04-30 | Merck & Co., Inc. | High-efficiency Cre/loxp based system for construction of adenovirus vectors |
US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
US8114414B2 (en) | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
WO1997003715A1 (en) | 1995-07-21 | 1997-02-06 | The General Hospital Corporation | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
JP2004500405A (ja) * | 2000-03-29 | 2004-01-08 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア | 抗原の免疫原性を増強するための組成物および方法 |
US20020150588A1 (en) | 2000-09-21 | 2002-10-17 | Allison James P. | SPAS-1 cancer antigen |
CA2486980A1 (en) * | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Attenuated listeria spp. and methods for using the same |
AU2003259109A1 (en) | 2002-07-12 | 2004-02-02 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US20050281783A1 (en) | 2003-10-15 | 2005-12-22 | Kinch Michael S | Listeria-based EphA2 vaccines |
US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US7858097B2 (en) * | 2004-08-13 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free Listeria strains and methods for constructing and using same |
US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
DK1991263T3 (en) * | 2006-03-01 | 2015-03-30 | Aduro Biotech | Prepared listeria and methods of use thereof |
US20080124354A1 (en) | 2006-07-10 | 2008-05-29 | Yvonne Paterson | Methods for administering tumor vaccines |
JP2010534058A (ja) * | 2007-04-16 | 2010-11-04 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 抗生物質耐性のないリステリア菌およびその構築および使用方法 |
EP2283112B1 (en) | 2008-05-19 | 2016-10-12 | Aduro Biotech | Compositions comprising prfa*mutant listeria and methods of use thereof |
GB201010389D0 (en) | 2010-06-21 | 2010-08-04 | Ist Superiore Sanita | Antibody derivatives |
US9200057B2 (en) | 2010-11-17 | 2015-12-01 | Providence Health & Services-Oregon | Methods and compositions for inducing an immune response to EGFRvIII |
EP2683400A4 (en) * | 2011-03-11 | 2014-09-17 | Advaxis | ADJUVANZIA ON LISTERIA BASE |
US10058599B2 (en) * | 2012-03-12 | 2018-08-28 | Advaxis, Inc. | Suppressor cell function inhibition following Listeria vaccine treatment |
-
2013
- 2013-12-27 SG SG11201502792TA patent/SG11201502792TA/en unknown
- 2013-12-27 AU AU2013370210A patent/AU2013370210B2/en not_active Ceased
- 2013-12-27 BR BR112015015076A patent/BR112015015076A2/pt active Search and Examination
- 2013-12-27 KR KR1020157015490A patent/KR102160322B1/ko active IP Right Grant
- 2013-12-27 US US14/142,614 patent/US9663557B2/en not_active Expired - Fee Related
- 2013-12-27 WO PCT/US2013/078119 patent/WO2014106123A1/en active Application Filing
- 2013-12-27 EP EP13869448.4A patent/EP2938627B1/en not_active Not-in-force
- 2013-12-27 MX MX2015008329A patent/MX2015008329A/es unknown
- 2013-12-27 JP JP2015550820A patent/JP2016503655A/ja active Pending
- 2013-12-27 SG SG10201700916SA patent/SG10201700916SA/en unknown
- 2013-12-27 EA EA201590397A patent/EA201590397A8/ru unknown
- 2013-12-27 CA CA2888727A patent/CA2888727A1/en not_active Abandoned
- 2013-12-27 CN CN201380068458.4A patent/CN104955835B/zh not_active Expired - Fee Related
-
2016
- 2016-03-16 HK HK16103082.5A patent/HK1215260A1/zh unknown
-
2017
- 2017-05-18 US US15/599,441 patent/US20170253637A1/en not_active Abandoned
-
2018
- 2018-04-06 JP JP2018074066A patent/JP6671408B2/ja not_active Expired - Fee Related
- 2018-05-21 AU AU2018203555A patent/AU2018203555A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2888727A1 (en) | 2014-07-03 |
EA201590397A8 (ru) | 2016-08-31 |
WO2014106123A1 (en) | 2014-07-03 |
AU2018203555A1 (en) | 2018-06-07 |
WO2014106123A8 (en) | 2016-06-16 |
KR102160322B1 (ko) | 2020-09-25 |
JP2016503655A (ja) | 2016-02-08 |
SG10201700916SA (en) | 2017-03-30 |
CN104955835A (zh) | 2015-09-30 |
AU2013370210B2 (en) | 2018-06-14 |
US20140186387A1 (en) | 2014-07-03 |
HK1215260A1 (zh) | 2016-08-19 |
EA201590397A1 (ru) | 2016-02-29 |
KR20150099738A (ko) | 2015-09-01 |
AU2013370210A8 (en) | 2016-06-23 |
SG11201502792TA (en) | 2015-05-28 |
US9663557B2 (en) | 2017-05-30 |
EP2938627A1 (en) | 2015-11-04 |
EP2938627A4 (en) | 2016-12-14 |
US20170253637A1 (en) | 2017-09-07 |
JP6671408B2 (ja) | 2020-03-25 |
AU2013370210A1 (en) | 2015-06-18 |
EP2938627B1 (en) | 2019-03-20 |
CN104955835B (zh) | 2020-04-17 |
BR112015015076A2 (pt) | 2018-10-30 |
JP2018135355A (ja) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015008329A (es) | Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. | |
AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
WO2009130618A3 (en) | Flagellin polypeptide vaccines | |
NZ753307A (en) | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof | |
MY173004A (en) | Mycobacterial antigen vaccine | |
EP2569436A4 (en) | RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF | |
WO2011140284A3 (en) | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses | |
EA201791806A1 (ru) | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов | |
MY184163A (en) | Transgene genetic tags and methods of use | |
NZ745324A (en) | Vaccines and vaccine components for inhibition of microbial cells | |
MX360415B (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
WO2019006401A3 (en) | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF | |
WO2012034025A3 (en) | Human cytomegalovirus vaccine | |
Wang et al. | Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B | |
PH12017502080A1 (en) | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same | |
Badell et al. | Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells | |
MY191217A (en) | Group a streptococcus vaccine | |
MX2019015769A (es) | Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno. | |
NZ760789A (en) | Uti fusion proteins | |
Gómez et al. | Multivalent fusion DNA vaccine against Brucella abortus | |
WO2010040847A3 (en) | Recombinant protein bodies as immunogen-specific adjuvants | |
WO2020065349A3 (en) | Vaccines and methods | |
Robinson et al. | Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections | |
IN2013CN01528A (es) |